On April 2, 2017 in an oral presentation at the American
Association for Cancer Research Annual Meeting 2017 in
Washington, D.C. (the AACR Annual Meeting), Jounce Therapeutics,
Inc. (the Company) presented preclinical data that support the
ongoing Phase 1/2 ICONIC trial of JTX-2011. JTX-2011 is an
agonist monoclonal antibody targeting Inducible T cell
CO-Stimulator (ICOS). A copy of the slide presentation is
attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1 attached hereto, is intended to be
furnished and shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such filing.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995, as amended, including, without
limitation, statements regarding plans and timelines for the
clinical development of JTX-2011; and the Companys ability to
implement its clinical development plans for JTX-2011. The words
may, will, could, would, should, expect, plan, anticipate,
intend, believe, estimate, predict, project, potential, continue,
target and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Any forward-looking
statements in this Current Report on Form 8-K are based on
managements current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained
in this Current Report on Form 8-K, including, without
limitation, risks and uncertainties related to the delay of any
current or planned clinical trials or the development of
JTX-2011; the Companys advancement of early-stage efforts; the
Companys ability to successfully demonstrate the efficacy and
safety of its product candidates; the preclinical and clinical
results for the Companys drug product candidates, which may not
support further development of such drug product candidates; and
actions of regulatory agencies, which may affect the initiation,
timing and progress of clinical trials; and the Companys ability
to develop and commercialize companion diagnostics for its
current and future drug candidates. These and other risks and
uncertainties are described in greater detail in the section
entitled Risk Factors in the Companys Annual Report on Form 10-K
for the fiscal year ended December 31, 2016, as filed with the
Securities and Exchange Commission (SEC) on March 10, 2017, and
other filings that the Company may make with the SEC in the
future. Any forward-looking statements contained in this Current
Report on Form 8-K represent the Companys views only as of the
date hereof and should not be relied upon as representing its
views as of any subsequent date. The Company explicitly disclaims
any obligation to update any forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits